Quote | Elevation Oncology Inc. (NASDAQ:ELEV)
Last: | $3.65 |
---|---|
Change Percent: | -5.93% |
Open: | $3.89 |
Close: | $3.88 |
High: | $3.92 |
Low: | $3.62 |
Volume: | 92,720 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
News | Elevation Oncology Inc. (NASDAQ:ELEV)
2024-04-22 11:00:17 ET Summary Elevation Oncology, Inc. has had a successful year, transitioning from the shelving of their seribantumab program to focusing on antibody-drug conjugates. Their flagship project, EO-3021, is a phase 1 study targeting Claudin-18.2 and has shown promis...
Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024 PR Newswire -- On-track to nominate development candidate in 2024 -- BOSTON , April 8, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an ...
Message Board Posts | Elevation Oncology Inc. (NASDAQ:ELEV)
Subject | By | Source | When |
---|---|---|---|
$ELEV Price gaining | Invest-in-America | investorshub | 04/22/2023 1:49:51 PM |
$ELEV MomentumIts gaining | Mt. Blanc | investorshub | 04/19/2023 3:56:59 PM |
Price trading last trade up | RNsidersbuying | investorshub | 04/19/2023 8:07:39 AM |
MomentumIts trading | Mt. Blanc | investorshub | 04/18/2023 12:38:48 AM |
are we finally gonna see some action | Mt. Blanc | investorshub | 04/16/2023 11:11:06 PM |
News, Short Squeeze, Breakout and More Instantly...
Elevation Oncology Inc. Company Name:
ELEV Stock Symbol:
NASDAQ Market:
Elevation Oncology Inc. Website:
Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024 PR Newswire -- On-track to nominate development candidate in 2024 -- BOSTON , April 8, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an ...
2024-03-29 05:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...